Next Article in Journal
Association of Non-Carious Cervical Lesions with Oral Hygiene Habits and Dynamic Occlusal Parameters
Previous Article in Journal
Evidence of Clinical Pathology Abnormalities in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) from an Analytic Cross-Sectional Study
Previous Article in Special Issue
Link-Level Functional Connectivity Neuroalterations in Autism Spectrum Disorder: A Developmental Resting-State fMRI Study
Article Menu

Export Article

Open AccessCase Report

Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases

1
SSD Oncology, Alghero General Hospital, 07041 Alghero, Italy
2
Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Traversa La Crucca 3, 07100 Sassari, Italy
3
Operative Unit of Pathology, Azienda Ospedaliero Universitaria Sassari, Via Matteotti 60, 07100 Sassari, Italy
4
Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081 Aviano, Italy
5
Radiotherapy Unit, Azienda Ospedaliero Universitaria Sassari, Via Matteotti 60, 07100 Sassari, Italy
6
Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081 Aviano, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(2), 42; https://doi.org/10.3390/diagnostics9020042
Received: 1 March 2019 / Revised: 2 April 2019 / Accepted: 9 April 2019 / Published: 11 April 2019
(This article belongs to the Special Issue Brain Imaging)
  |  
PDF [3376 KB, uploaded 7 May 2019]
  |     |  

Abstract

Most non-small-cell lung cancer (NSCLC) patients are likely to develop brain metastases during the course of their illness. Currently, no consensus on NSCLC patients’ treatment with brain metastasis has been established. Although whole brain radiotherapy prolongs the median survival time of approximately 4 months, a cisplatin-pemetrexed combination may also represent a potential option in the treatment of asymptomatic NSCLC patients with brain metastases. Herein, we report the case of a non-smoker male patient with multiple, large and diffuse brain metastases from an “epidermal growth factor receptor (EGFR) wild-type” lung adenocarcinoma who underwent an overly aggressive chemo/radiation therapy. This approach led to a complete and durable remission of the disease and to a long survival of up to 58 months from diagnosis of primary tumor. The uncommon course of this metastatic disease induced us to describe its oncological management and to investigate the molecular features of the tumor. View Full-Text
Keywords: lung cancer; EGFR; brain metastases; radiotherapy; chemotherapy; CDH1; TP53; tumor mutational burden lung cancer; EGFR; brain metastases; radiotherapy; chemotherapy; CDH1; TP53; tumor mutational burden
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Santeufemia, D.A.; Palmieri, G.; Cossu, A.; De Re, V.; Caggiari, L.; De Zorzi, M.; Casula, M.; Sini, M.C.; Baldino, G.; Dedola, M.F.; Corona, G.; Miolo, G. Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases. Diagnostics 2019, 9, 42.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top